Company Overview
Company Type: Public Company
Website: www.resverlogix.com
Number of Employees: 19
Ticker: RVX (TSX)
Year Founded: 2001


Business Description
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
19.0
EBITDA
(8.5)
Total Enterprise Value
107.2
TEV/EBITDA
NM
EBIT
(8.9)
Cash & ST Invst.
0.1
P/Diluted EPS Before Extra
NM
Net Income
(13.8)
Total Debt
91.6
Price/Tang BV
NM
Total Assets
10.8
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
McCaffrey, Donald J.
Co-Founder, Chairman, President, CEO & Secretary
Cann, Aaron Bradley
Chief Financial Officer
Kulikowski, Ewelina 
Chief Scientific Officer
Zapotichny, Sarah 
Director of Investor Relations & Corporate Communications
Sweeney, Michael 
Senior Vice President of Clinical Development

Key Board Members
Name
Title
McCaffrey, Donald J.
Co-Founder, Chairman, President, CEO & Secretary
McNeill, Kelly Bret
Independent Director
Zuerblis, Kenneth J.
Independent Director
Lu, Shawn 
Director
To, Siu Lun 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
4820 Richard Road SW Suite 300 | Calgary, AB | T3E 6L1 | Canada
Phone: 403-254-9252   Fax: 403-256-8495

Current and Pending Investors
Eastern Capital Limited, Efung Capital (Jinqiao Zhu), NGN Capital (Peter Johann), Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399), Shenzhen Lucky Source Funds Management Co., Ltd., Yorkville Advisors Global LP

Prior Investors
i3 Capital Partners Inc., Investment Arm

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.07
Market Cap (mm)
19.0
Open
 0.07
Shares Out. (mm)
271.7
Previous Close
 0.07
Float %
66.3%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.07/ 0.07
Diluted EPS Excl. Extra Items
(0.05)
52 wk High/Low
 0.26/ 0.07
P/Diluted EPS Before Extra
NM
Volume (mm)
0.02
Avg 3M Dly Vlm (mm)
0.11
Beta 5Y
0.68


 
Delayed Quote** | Last Updated on Oct-04-2023 12:00 AM (GMT-5)
TSX:RVX - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Apsley Management Group Inc.
As of April 24, 2003 Apsley Management Group Inc. was acquired by Resverlogix Inc., in a reverse merger transaction.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-05-2021
-
Private Placement
Target
Resverlogix Corp. (TSX:RVX)
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399)

6.00
Nov-30-2020
Nov-30-2020
Private Placement
Target
Resverlogix Corp. (TSX:RVX)


0.61
Oct-06-2020
-
Private Placement
Target
Resverlogix Corp. (TSX:RVX)


9.94
Aug-14-2020
Aug-14-2020
Private Placement
Target
Resverlogix Corp. (TSX:RVX)
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399)

2.02
May-31-2020
May-31-2020
Private Placement
Target
Resverlogix Corp. (TSX:RVX)


0.35
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-20-2023
Annual General Meeting
Resverlogix Corp., Annual General Meeting, Jun 20, 2023
Jun-20-2023
Shareholder/Analyst Calls
Resverlogix Corp. - Shareholder/Analyst Call
Mar-31-2023
Auditor Going Concern Doubts
Resverlogix Corp. Auditor Raises 'Going Concern' Doubt
Mar-05-2023
Company Conference Presentations
Resverlogix Corp. Presents at ACC.23 Together With The 2023 World Congress of Cardiology, Mar-05-2023
Jan-09-2023
Company Conference Presentations
Resverlogix Corp. Presents at Biotech Showcase 2023, Jan-09-2023


Advisors
Most Recent Auditor
RSM US LLP
Private Placement Advisors
Bloom Burton & Co. Inc., Canaccord Genuity Corp., Caris & Company, Inc., CIBC World Markets Corp., Cormark Securities Inc., Direct Markets Holdings Corporation, Gundy and Associates Limited, Haywood Securities Inc., Jennings Capital Inc., Loewen Ondaatje McCutcheon Limited, Investment Banking Arm, Macquarie Private Wealth Inc., MLV & Co. LLC, National Bank Financial, Inc., NBCN Inc., Northern Securities Inc., Oppenheimer & Co. Inc., Raymond James Ltd., Wolverton Securities Ltd
Public Offering Advisors
Borden Ladner Gervais LLP, KPMG LLP (Canada), Wedbush Securities Inc.
Key development Advisor
UBS Investment Bank


Most Recent Auditor
McGladrey LLP - RSM  LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:28 AM
RVX
Resverlogix Corp 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 06:37 AM
RVX
ValuEngine - Toronto Quantitative Stock Report for RVX
Reports
5
Jefferson Research & Management

Sep 15, 2023 01:00 PM
RVX
Jefferson Financial - Resverlogix Corp.
Reports
11
GlobalData

Sep 15, 2023 04:04 AM
RVX
Resverlogix Corp (RVX.TSE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
128
MarketLine

Sep 14, 2023 06:01 AM
RVX
Resverlogix Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
448
GlobalData

Sep 12, 2023 04:01 AM
RVX
Resverlogix Corp (RVX.TSE) - Financial Analysis Review
Reports
280
Jefferson Research & Management

Sep 08, 2023 01:02 PM
RVX
Jefferson Financial - Resverlogix Corp.
Reports
11
S&P Global Compustat

Sep 07, 2023 03:14 AM
RVX
Resverlogix Corp 2023_09_07
Reports
14
Jefferson Research & Management

Sep 01, 2023 01:01 PM
RVX
Jefferson Financial - Resverlogix Corp.
Reports
11
GlobalData

Aug 29, 2023 01:58 AM
RVX
Resverlogix Corp (RVX.TSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
59


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

85,286,524

31.39

6.0

May-10-2023


Eastern Capital Limited

27,712,879

10.20

1.9

May-10-2023


McCaffrey, Donald J.

5,263,266

1.94

0.4

Jul-14-2023


Cann C.A., CPA, CA, CPA, CBV, Aaron Bradley

592,490

0.22

0.0

Sep-15-2023


Sweeney M.D., Michael 

155,312

0.06

0.0

Mar-03-2023


Zuerblis CPA, CPA, Kenneth J.

107,062

0.04

0.0

Jun-30-2023


McNeill B.Comm (Hons), C.A., C.P.A., CA, CPA, M.Acc, Kelly Bret

105,000

0.04

0.0

Jun-30-2023


Kulikowski Ph.D., Ewelina 

66,500

0.02

0.0

Mar-03-2023


Johansson M.D., Ph.D., Jan O.

0

0.00

0.0

Jun-26-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Cann C.A., CPA, CA, CPA, CBV, Aaron Bradley
592,490
73,684

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Johansson M.D., Ph.D., Jan O.
0
(117,360)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Apabetalone (Future), NexVas Alzheimer’s Disease Technology (Future), NexVas Plaque Regression Program (Future), ReVas (Future), TGF-ß Shield (Future)


Upcoming Events
Date/Time
Type
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-04-2023
-
Resverlogix Corp. (TSX:RVX)
SEDAR
News Releases
49 KB
Aug-11-2023
Jun-30-2023
Resverlogix Corp. (TSX:RVX)
SEDAR
Interim Financial Statements
298 KB
Jun-29-2023
-
Resverlogix Corp. (TSX:RVX)
SEDAR
News Releases
50 KB
Jun-20-2023
-
Resverlogix Corp. (TSX:RVX)
SEDAR
News Releases
33 KB
Jun-20-2023
-
Resverlogix Corp. (TSX:RVX)
SEDAR
Management Proxy Materials
82 KB
Jun-12-2023
-
Resverlogix Corp. (TSX:RVX)
SEDAR
News Releases
49 KB
May-16-2023
-
Resverlogix Corp. (TSX:RVX)
SEDAR
Management Proxy Materials
79 KB
May-16-2023
-
Resverlogix Corp. (TSX:RVX)
SEDAR
Management Proxy Materials
172 KB
May-16-2023
-
Resverlogix Corp. (TSX:RVX)
SEDAR
Management Proxy Materials
147 KB
May-16-2023
-
Resverlogix Corp. (TSX:RVX)
SEDAR
Management Proxy Materials
791 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Cann C.A., CPA, CA, CPA, CBV, Aaron Bradley (Chief Financial Officer)
Sep-15-2023
Common Shares
50,000
-
Derivative Exercise and Retained Stock
9.22
Multiple
Cann C.A., CPA, CA, CPA, CBV, Aaron Bradley (Chief Financial Officer)
Sep-13-2023
Common Shares
50,000
-
Derivative Exercise and Retained Stock
10.15
Multiple
Cann C.A., CPA, CA, CPA, CBV, Aaron Bradley (Chief Financial Officer)
Aug-14-2023 - Aug-16-2023
Common Shares
(289,002)
(7,727)
Derivative Exercise and Sale
-
Multiple
-
Aug-14-2023
Common Shares
58,334
0
Derivative Exercise
-
Exchange Announcement
-
Aug-16-2023
Common Shares
38,000
0
Derivative Exercise
-
Exchange Announcement
-
Aug-14-2023
Common Shares
58,334
0
Derivative Exercise
-
Exchange Announcement
-
Aug-16-2023
Common Shares
38,000
0
Derivative Exercise
-
Exchange Announcement
-
Aug-15-2023
Common Shares
(58,000)
(5,912)
Sale
-
Exchange Announcement
-
Aug-15-2023
Common Shares
(58,000)
(5,912)
Sale
-
Exchange Announcement
-
Aug-16-2023
Common Shares
(38,000)
(3,864)
Sale
-
Exchange Announcement
-
Aug-16-2023
Common Shares
(38,000)
(3,864)
Sale
-
Exchange Announcement
Cann C.A., CPA, CA, CPA, CBV, Aaron Bradley (Chief Financial Officer)
Jul-25-2023
Common Shares
50,000
0
Derivative Exercise and Retained Stock
11.31
Multiple
Cann C.A., CPA, CA, CPA, CBV, Aaron Bradley (Chief Financial Officer)
Jul-24-2023
Common Shares
(50,000)
(5,628)
Open Market Disposition
(9.22)
Multiple
-
Jul-24-2023
Common Shares
(20,000)
(2,189)
Open Market Disposition
-
Exchange Announcement
-
Jul-24-2023
Common Shares
(30,000)
(3,440)
Open Market Disposition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
McCaffrey, Donald J.
Co-Founder, Chairman, President, CEO & Secretary
403-254-9252
403-256-8495
don@resverlogix.com
McNeill, Kelly Bret
Independent Director
403-254-9252
403-256-8495

Zuerblis, Kenneth J.
Independent Director
403-254-9252
403-256-8495

Lu, Shawn 
Director
403-254-9252
403-256-8495

To, Siu Lun 
Independent Director
852 3898 1506
852 3898 1599

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
McCaffrey, Donald J.
Co-Founder, Chairman, President, CEO & Secretary
403-254-9252
403-256-8495
don@resverlogix.com
Cann, Aaron Bradley
Chief Financial Officer
(888) 259-9899
(403) 259-8580

Kulikowski, Ewelina 
Chief Scientific Officer
403-254-9252
403-256-8495

Zapotichny, Sarah 
Director of Investor Relations & Corporate Communications
403-254-9252
403-256-8495
sarah@resverlogix.com
Sweeney, Michael 
Senior Vice President of Clinical Development
403-254-9252
403-256-8495

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
